Store

Home | Store | Cell and Gene Therapy Funding and Deals Analysis, 2021-2023

Cell and Gene Therapy Funding and Deals Analysis, 2021-2023

Publication Date: December 8, 2023

LICENSE

Clear

SKU: 23-023

Tags: CAR-T Cell Therapy, Cell and Gene Therapy, Funding and Investments, Life Science, Mergers and Acquisitions (M&A), Oncology and Cancer

Pages: 290

SKU: 23-023

Explore the dynamic world of cell and gene therapy deal-making with Kalorama Information’s comprehensive report, Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023. This report tracks the deal-making activities in cell and gene therapy since 2021, providing insightful graphs of quarterly trends from 2021-2023 and detailing over 2,000 deals covering the Q1 2022-Q3 2023 period.

Key Features:

In-depth analysis of over 2,000 deals in the cell and gene therapy sector
Overview of quarterly funding amounts from 2021-2023
Detailed breakdown of deal types, including Technology/Research/Strategic Collaboration, Venture Capital/Private Investment, Acquisition, Merger, Strategic Investment, and more
Identification of the most active deal-making companies and their involvement in various types of deals
Regional breakdown of deal-making activities in North America, Europe, APAC, and Rest of World

Market Insights:

The report highlights the significant growth and evolution of the cell and gene therapy sector, driven by advancements in enabling technologies such as CRISPR and next-generation sequencing. With over 1,500 therapy or tools companies now involved in this field, the market has become highly competitive, with over $20 billion in deals tracked in the first three quarters of 2023 alone.

Why Choose Kalorama Information’s Report?

Kalorama’s report provides a comprehensive overview of the current cell and gene therapy deal-making landscape, offering valuable insights for companies entering or already operating in this market. With detailed analysis of deal trends, funding amounts, and regional activities, this report is essential for understanding the dynamics that will shape the future of cell and gene therapy.

As the cell and gene therapy market continues to grow rapidly, understanding the deal-making landscape is crucial for identifying opportunities and staying competitive. Kalorama’s report offers unparalleled insights into the market, making it a valuable resource for companies looking to navigate the complex world of cell and gene therapy deal-making.

Table: Total Quarterly Funding, by Type, Q1-Q3 2023 ($M)

Type	Q1	Q2	Q3	Partial ’23	’23 share
M&A	$XX Million	$XX Million	$XX Million	$XX Million	XX%
VC/private	$XX Million	$XX Million	$XX Million	$XX Million	XX%
IPO/FPO	$XX Million	$XX Million	$XX Million	$XX Million	XX%
Collaboration payments	$XX Million	$XX Million	$XX Million	$XX Million	XX%
SPAC	$XX Million	$XX Million	$XX Million	$XX Million	XX%
Strategic investments	$XX Million	$XX Million	$XX Million	$XX Million	XX%
Total	$XX Million	$XX Million	$XX Million	$XX Million	XX%

Source: Kalorama Information

For further details and to purchase directly, please contact us.

Chapter 1: Executive Summary

Introduction

$27.1 Billion in Investment in First Nine Months of 2023

Figure 1-1: Total Deals per Month, Apr 2021-Sep 2023 (count)
Figure 1-2: Total Deals per Month by Type, Apr 2021-Sep 2023 [VC/Private, IPO/FPO/SPAC; and All Other Deals] (count)

Quarterly Funding Amounts

Table 1-1: Total Quarterly Funding, by Type, Q1-Q3 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Table 1-2: Total Quarterly Funding, by Type, 2022 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Table 1-3: Total Quarterly Funding, by Type, 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Figure 1-3: Total Quarterly Funding, Q1 2021- Q3 2023 ($M)
Figure 1-4: Total Quarterly Funding, by Type, Q1 2021-Q3 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)

Quarterly Funding Category Shares, Q1 2021 Through Q3 2023

Table 1-4: Total Quarterly Funding Share, by Type, 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Table 1-5: Total Quarterly Funding Share, by Type, 2022 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Table 1-6: Total Quarterly Funding Share, by Type, 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Figure 1-5: Total Quarterly Funding Share, by Type, Q1 2021-Q3 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-6: 2021 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-7: 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-8: 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)

Quarterly Deal Counts by Category, Q1 2021 – Q3 2023

Table 1-7: Quarterly Count of Deals, By 2023 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
Table 1-8: Quarterly Count of Deals, by 2022 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
Table 1-9: Quarterly Count of Deals, by 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
Table 1-10: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation], 2021-2023 partial (%)

Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy

Figure 1-9: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation], 2021-2023 partial (%)
Figure 1-10: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain], 2021-2023 partial (Total number)

A Look at Less Frequent CGT Deal Types

Figure 1-11: Lower Frequency Deal Types, by Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
Figure 1-12: Merger/ Acquisition Amount, by Quarter [Q1 2021 – Q3 2023] ($M)
Figure 1-13: Venture Capital/Private Funding Round Amount, by Quarter [Q1 2021-Q3 2023] ($M)
Figure 1-14: IPO/FPO Amount, by Quarter [Q1 2021-Q3 2023] ($M)
Figure 1-15: SPAC Portion Amount, by Year 2021-2023 ($M)

Most Active Companies

Table 1-11: Most Active Companies in CGT Deals, Collaborations, Overall 2021-2023
Figure 1-16: Most Active Companies in CGT Deals, Collaborations, Overall 2021-2023

Chapter 2: Venture Capital & Private Funding

VC/Private Funding in Flux

Figure 2-1: Total Number of VC/Private Funding Deals by Month, Jan 2021-Sep 2023 (count)

Figure 2-2: Average VC/Private Funding Round Amount, by Quarter Q1 2021- Q1 2023 ($M)
Table 2-1: Regional Venture Capital/Private Funding, by Quarter Q1 2021-Q3 2023, by Region[North America, Europe, APAC, Rest of World] ($M) (%)
Figure 2-3: Quarterly Venture Capital/Private Total Funding, Q1 2021- Q1 2023, by Region [North America, Europe, APAC, Rest of World] ($M)
Table 2-2: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021-Q3 2023, [North America, Europe, APAC, Rest of World] (%)
Figure 2-4: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021-Q3 2023, by Region [North America, Europe, APAC, Rest of World] (%)
Figure 2-5: Venture Capital/Private Funding Round Amounts, By Quarter [Q1 2021-Q3 2023] ($M)
Figure 2-6: Scaled Venture Capital/Private Funding Round Amounts, By Quarter [Q1 2021-Q3 2023] ($M)
Table 2-3: Venture Capital/Private Fundraising Deals, Q3 2023
Table 2-4: Venture Capital/Private Fundraising Deals, Q2 2023
Table 2-5: Venture Capital/Private Fundraising Deals, Q1 2023
Table 2-6: Venture Capital/Private Fundraising Deals, Q4 2022
Table 2-7: Venture Capital/Private, Q3 2022
Table 2-8: Venture Capital/Private Fundraising Deals, Q2 2022
Table 2-9: Venture Capital/Private Fundraising Deals, Q1 2022

Chapter 3: Strategic Investments

Strategic Investments in Cell and Gene Therapy

Figure 3-1: Total Number of Strategic Investments, By Quarter [Q1 2021-Q3 2023] (count)
Figure 3-2: Average Strategic Investment Amount, By Quarter [Q1 2021-Q3 2023] ($M)
Figure 3-3: Total Strategic Investments, By Quarter [Q1 2021-Q3 2023] ($M)
Table 3-1: Strategic Investment Total Amounts, Counts, and Averages by Quarter, Q1 2021-Q3 2023, ($M)
Table 3-2: Strategic Investments, January 2021-September 2023
Table 3-3: Most Active in Acquisition/Merger/Strategic Investment, 2021-2023
Figure 3-4: Most Active in Acquisition/Merger/ Strategic Investment, 2021-2023

Chapter 4: IPOs, FPOs, & SPACs

North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs

Figure 4-1: Total Number of IPOs/ FPOs, By Month [Jan 2021-Sep 2023] (count)
Figure 4-2: Average IPO/FPO Proceeds, By Quarter [Q1 2021-Q3 2023] ($M)
Table 4-1: Quarterly IPO/FPO Total Funding, Q1 2021-Q3 2023, by Region [North America, Europe, APAC] ($M)
Figure 4-3: Total IPO/FPO Funding, By Quarter [Q1 2021-Q3 2023], by Region [North America, Europe, APAC] ($M)
Table 4-2: Regional IPO/FPO Funding Shares, by Quarter, Q1 2021-Q3 2023, by Region [North America, Europe, APAC] (%)
Figure 4-4: Regional IPO/FPO Funding Shares, By Quarter, Q1 2021-Q3 2023, by Region [North America, APAC, and Europe) (%)
Figure 4-5: IPO/FPO Amounts, By Quarter [Q1 2021-Q3 2023] ($M)
Table 4-3: Quarterly SPAC Funding Portion, Q1 2021-Q3 2023 ($M)
Figure 4-6: Quarterly SPAC Funding Portion Total and Average, Q1 2021-Q3 2023 ($M)
Table 4-4: IPO/FPO Deals, Q3 2023
Table 4-5: IPO/FPO Deals, Q2 2023
Table 4-6: IPO/FPO Deals, Q1 2023
Table 4-7: IPO/FPO Deals, Q4 2022
Table 4-8: IPO/FPO Deals, Q3 2022
Table 4-9: IPO/FPO Deals, Q2 2022
Table 4-10: IPO/FPO Deals, Q1 2022
Table 4-11: SPAC Portion, January 2021-September 2023 ($M)
Figure 4-7: SPAC Portion Amount, by Year, 2021-2023 ($M)

Chapter 5: Mergers & Acquisitions (M&A)

Growing Numbers of M&A, Despite Lower Average Value

Figure 5-1: Total Number of Mergers and Acquisitions, By Month [Jan 2021-Sep 2023] (count)
Figure 5-2: Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q3 2023] ($M)
Table 5-1: Quarterly Merger and Acquisition Values, Counts, and Averages, Q1 2021-Q3 2023 ($M) (Total count)
Figure 5-3: Merger/Acquisition Transactions Global Total, By Quarter [Q1 2022- Q3 2023] ($M)
Figure 5-4: Merger/Acquisition Amounts, by Quarter [Q1 2021-Q3 2023] ($M)
Table 5-2: Mergers and Acquisitions Announcements, Q3 2023 ($M)
Table 5-3: Mergers and Acquisitions Announcements, Q2 2023 ($M)
Table 5-4: Mergers and Acquisitions Announcements, Q1 2023 ($M)
Table 5-5: Mergers and Acquisitions, Q4 2022 ($M)
Table 5-6: Mergers and Acquisitions, Q3 2022 ($M)
Table 5-7: Mergers and Acquisitions, Q2 2022 ($M)
Table 5-8: Mergers and Acquisitions, Q1 2022 ($M)
Table 5-9: Most Active in Acquisition/Merger/Strategic Investment, 2021-2023 (count)
Figure 5-5: Most Active in Acquisition/Merger/Strategic Investment, 2021-2023

Chapter 6: Technology/Research/Strategic Collaborations

CGT Market Sees a Broad Variety of Collaborations

Figure 6-1: Total Number of Tech/Research/Strategic Collaborations, By Month [Jan 2021-Sep 2023] (count)
Figure 6-2: Total Number of Collaborations with Upfront and/or Milestone Payments, By Quarter [Q1 2021-Q3 2023] ($M)
Table 6-1: Collaboration Upfront and Future/Milestone Payments, Counts, Averages, Q1 2021-Q3 2023 ($M) (count)
Figure 6-3: Average Collaboration Upfront Payment, By Quarter [Q1 2021-Q3 2023] ($M)
Figure 6-4: Research Collaboration Upfront Payments, By Quarter [Q1 2021-Q3 2023] ($M)
Figure 6-5: Average Collaboration Future/Milestone Payments, By Quarter [Q1 2021-Q3 2023] ($M)
Figure 6-6: Total Collaboration Future/Milestone Payments, By Quarter [Q2 2021-Q3 2023] ($M)
Table 6-2: Technology/Research/Strategic Collaboration Deals, Q3 2023
Table 6-3: Technology/Research/Strategic Collaboration Deals, Q2 2023
Table 6-4: Technology/Research/Strategic Collaboration Deals, Q1 2022–Q3 2023
Table 6-5: Most Active in Research/Strategic Collaborations, 2021-2023 (count)
Figure 6-7: Most Active in Research/Strategic Collaborations, 2021-2023 (count)

Chapter 7: Licensing

Stable Levels of Licensing in the Cell and Gene Therapy Market

Figure 7-1: Total Number of Licensing Deals, By Month [Jan 2021-Sep 2023] (count)
Table 7-1: Licensing Deals, Q3 2023
Table 7-2: Licensing Deals, Q2 2023
Table 7-3: Licensing Deals, Q1 2022-Q1 2023
Table 7-4: Most Active Companies in Licensing Deals, 2021-2023 (count)
Figure 7-2: Most Active Companies in Licensing Deals, 2021-2023 (count)

Chapter 8: Manufacturing and Supply Chain

Major Growth in Manufacturing and Supply Chain Management Activity in CGT

Figure 8-1: Total Number of Supply/ Manufacturing Deals, By Month [Jan 2021-Sep 2023] (count)
Table 8-1: Manufacturing and Supply Chain Deals, Q3 2023
Table 8-2: Manufacturing and Supply Chain Deals, Q2 2023
Table 8-3: Manufacturing and Supply Chain Deals, Q1 2022-Q3 2023
Table 8-4: Most Active Companies in Manufacturing/ Supply Deals, 2021-2023 (count)
Figure 8-2: Most Active Companies in Manufacturing/ Supply Deals, 2021-2023 (count)

Chapter 9: Public Outreach, Education, & Philanthropy

CGT Market Focusing Less on Public Outreach, Patient/ Consumer/ Trainee Education, and Philanthropy

Figure 9-1: Total Number of Outreach/ Philanthropy/ Education Deals, By Month [Jan 2021-Sep 2023] (count)
Table 9-1: Outreach, Education, & Philanthropy Deals, January 2022-Aug 2023

Chapter 10: Distribution & Co-Marketing

A Look at CGT Distribution and Co-Marketing Deals

Figure 10-1: Total Number of Distribution/ Co-Marketing Deals, by Month [Jan 2021-Sep 2023] (count)
Table 10-1: Distribution & Co-Marketing Deals, Q3 2023
Table 10-2: Distribution & Co-Marketing Deals, Q2 2023
Table 10-3: Distribution & Co-Marketing Deals, Q1 2022-Q1 2023

Chapter 11: Other – JV, Restructuring, Termination, Spinoffs

A Look at Other Types of Deals Impacting Cell and Gene Therapy

Figure 11-1: Total Number of JV, Restructuring, Termination, By Month [Jan 2021-Sep 2023] (Total count)
Table 11-1: Restructuring, JV, Termination, Spinoffs, January 2022-Sep 2023

Related products

IVD Market Trends Report, March 2023

March 17, 2023

Diagnostic testing remains a cornerstone in healthcare, aiding physicians in diagnosis and providing crucial information for treatments like precision medicine. As we navigate the aftermath of the COVID-19 pandemic, the IVD market is evolving, driven by new products, shifts in global health spending, regulatory updates, and changing disease trends. Despite these shifts, the IVD market…

$3,000.00 – $4,500.00

Cell Therapy and Gene Therapy Disease Markets, 2023-2029

April 30, 2024

Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in…

$5,000.00 – $7,875.00

The World Market for Veterinary Diagnostics, 7th Edition

January 22, 2024

Unlock the potential of the veterinary diagnostics market with Kalorama Information’s comprehensive report, The World Market for Veterinary Diagnostics, 7th Edition, which dives deep into the world of animal healthcare diagnostics. From disease identification to monitoring, veterinarians rely on a variety of tests for accurate diagnoses and effective treatment plans. Our report provides a detailed…

$5,000.00 – $7,875.00

Hematology and Coagulation Markets, 2023

Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.

Key Insights Provided:

Market sizing…

$3,000.00 – $4,500.00

Cell and Gene Therapy Market and Deals Analysis, 2023

Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals tracks deal-making and market opportunities in cell and gene therapy, providing specific details of 1000+ deals from 2022-2023. With a staggering $40 billion in CGT deals in 2022 alone, understanding the market dynamics and key…

$4,000.00 – $6,000.00

Cell and Gene Therapy Deals Analysis, 2021-2024

Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and…

$6,300.00 – $9,450.00